Call Us Today! 1.703.664.2407|office@nationalbreastcenter.com

site_admin

About David Weintritt

This author has not yet filled in any details.
So far David Weintritt has created 6 entries.

Advancements in Breast Cancer Technology: The SPY Portable Handheld Imager (SPY-PHI)

National Breast Center Lead Site for Groundbreaking Device used in Breast Cancer Surgery

 

We understand how powerful it can be to hear the words: “you are clear of cancer.“ This peace of mind is something that a revolutionary new imaging technology provides to breast cancer patients in need to knowing if their cancer has spread. As we work with patients to identify cancer, then work to treat and/or remove cancer, we’ve always been unable to determine 100 percent if the cancer was removed entirely. Now, using the new SPY Portable Handheld Imager (SPY-PHI), manufactured by NOVADAQ Technologies Inc., surgeons can identify if all the cancer cells have been removed, with absolute certainty. The SPY-PHI device allows surgeons to visualize blood flow and related tissue perfusion in real time with its Fluorescence Imaging Technology.

 

Having access to this one-of-a-kind piece of technology allows us to have a reliable and objective way to assess blood flow and follow the pathway of cancer. As a result, we can confidently inform patients on the best course of action in their journey to recovery.

 

National Breast Center is currently one of the lead sites to have access to this FDA-approved state-of-the-art device and continues to stay on the cutting edge of innovations in breast cancer surgery.

 

The National Breast Center combines advanced technology and over a decade of specialized surgical training with a truly personalized focus on breast health.

 

For more information on the SPY-PHI device, please call us at 703-664-2407 or email us at office@nationalbreastcenter.com

BioZorb® Helps Minimize Patient Exposure to Radiation

Dissolving Implantable Device Guides Targeting and Application of Treatments
Patients battling cancer are often uneasy about potential side effects that can last long after they are free of the disease. Here at National Breast Center, we do everything possible to ensure our patients have options that can reduce the amount of radiation given while improving the accuracy.

 

This helps relieve anxiety about the impact of the care they receive and places them in a more positive state of mind. One of the keys to that mission is the innovative BioZorb® implantable device from Focal Therapeutics. Most National Breast Center patients who undergo a lumpectomy or partial mastectomy receive the BioZorb®. The FDA-approved device acts as a three-dimensional marker to show specifically where the excised cancer tumor was located, providing pinpoint precision for positioning radiation treatments. Without such guidance, radiation oncologists are often forced to treat larger areas of the breast with higher doses of radiation. With BioZorb®, the patient receives radiation precisely at the site of the cancer resulting in fewer complications and better outcomes. The BioZorb® does not interfere with healing, the existing surgical plan, or surgical breast reconstructions, and eventually dissolves harmlessly within the body.

 

Six tiny and benign titanium chips remain at the surgical site to guide future imaging and assist in quickly detecting any recurrences of cancer. Access to cutting edge technology like this allows our patients to have the best outcomes possible.

 

For questions about BioZorb® please call us at 703-664-2407 or email us at office@nationalbreastcenter.com

MammaPrint Test Helps Optimize Breast Cancer Care

National Breast Center’s Use of Personalized Medicine Focuses on Care and Avoids Unnecessary Treatments

 

Personalized medicine is the future of cancer care. It is a course of treatment tailored to the needs and genetic makeup of the individual patient. Providing customized care is a powerfully reassuring experience that gives each patient the confidence they have the best chance possible of conquering their illness. At the National Breast Center, that begins with MammaPrint® test from Agendia, Inc. MammaPrint® is an FDA-approved, molecular-level test that examines 70 different genetic factors associated with each case of breast cancer. It can determine whether a patient has a low or high risk of a recurrence of their cancer. A low risk score means there is a one in 10 chance that breast cancer may recur at a future time. A high risk score means there is a three in 10 chance or greater of a breast cancer recurrence. MammaPrint® eliminates an intermediate risk score, where it’s unknown if the risk for a cancer recurrence is low or high. An indeterminate score was once associated with nearly 40 percent of breast cancer cases, and often made courses of care unnecessarily aggressive and grueling for patients. MammaPrint® risk scoring helps Dr. Weintritt and his team at National Breast Center determine the best course of treatment for patients and guarantee that the patient will not undergo any unnecessary chemotherapy or other treatments.

For questions about MammaPrint®, please call us at 703-664-2407 or email us at office@nationalbreastcenter.com

National Breast Center October Brunch

National Breast Center October Brunch Coming to the Ritz Carlton Pentagon City
Non Profit Hosts Event for Breast Cancer Awareness Month
Pentagon City, VA: The National Breast Center, will host a fundraiser during the month of October to recognize Breast Cancer Awareness month. The event will be held on Sunday, October 26, 2014 at the Ritz Carlton in Pentagon City, VA beginning with a VIP reception at 11 am and followed by brunch at 12:30 pm.

The event is designed to bring the community together to honor Breast Cancer Awareness month, to increase knowledge about screening and treatment options, and to launch this newly formed organization and it’s programs. The brunch will also honor cancer survivors and medical professionals who advocate for breast cancer patients, and will outline plans the Center has to help women in the community.

“There are tools that use cutting-edge technology to improve the diagnosis and treatment of breast cancer that are available in our community. Unfortunately they are utilized in less than 20% of women that would benefit from them…We know how to fix these problems, and every day, women in our clinic benefit from our unique approach. We want to touch more lives in more ways and improve the availability and quality of breast cancer care,” said Dr. David C. Weintritt, MD FACS, board certified breast surgeon and founder of the National Breast Center.

Funds raised at the event will help the foundation with their mission to improve the lives of women by removing barriers that prevent proper screening, diagnosis, and education about treatments available. They are committed to setting the standard in improving outcomes through education, personalized risk assessment, access to care, and support during treatments for anyone diagnosed with breast cancer.

Sponsorships […]

Dr. Weintritt’s Response to the New York Times

Ignoring the Science on Mammograms
While the focus related to breast cancer always will and should be survival, there are many other important issues that women with breast cancer face. There are many steps involved in successfully treating breast cancer. Surgery, medications including chemotherapy and hormonal therapy, and radiation are all part of treating breast cancer. What many women and even some physicians aren’t aware of is how many options exist within each of these treatments and how varied the cumulative effort required to achieve survival can be.

Screening mammography, especially in it’s newest form of digital and even 3D studies, is capable of finding breast cancers that are only millimeters in size. When this happens, women are able to look at a much simpler path to survival. Less invasive surgical procedures, less intense medical regimens, and shorter, more focused courses of radiation. Quality of life is not measured as much as overall survival, but why would we shy away from giving women more options with fewer side effects? The majority of women diagnosed with breast cancer will survive. Let’s make sure we acknowledge how different, and sometimes unnecessarily difficult the path to success can be and focus on making it as easy as possible.

Dr. David C. Weintritt, MD FACS
Breast Surgeon
Founder, National Breast Center

Read the Original Article: Ignoring the Science on Mammograms